Share Price:

APNASPENAspen Pharmacare Hldgs16630-129 (-0.77%)

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Aspen delivers strong results and advances its strategic ambitions

Stephen Saad Aspen Group Chief Executiv

Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.

Aspen announces local availability of Lilly’s Mounjaro

Stephen Saad, Aspen Group Chief Executive

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.

Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day

Heinz Schütte, Aspen Pharmacare Regional CEO, Dr Reyna Daya, SEMDSA President & Endocrinologist, and Stavros Nicolau, Aspen Group Senior Executive Strategic Trade

Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.

Aspen’s revenue increases 10% underpinned by a strong second half performance

Stephen Saad Aspen Group Chief Executiv

JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.